The use of combined intravenous pulse methylprednisolone and oral cyclosporin A in the treatment of corneal graft rejection: A preliminary study

Eye

Volumn 12, Issue 4, 1998, Pages 615-618

  Lam, Dennis S C ^a   Wong, Angus K K ^a   Tham, Clement C Y ^a   Leung, Alfred T S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Corneal graft rejection; Cyclosporin A; Intravenous methylprednisolone

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA TRANSPLANTATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DUODENUM ULCER; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; SCHOOL CHILD; TIME; TREATMENT OUTCOME;

EID: 0031708437     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.1998.154     Document Type: Article

References (29)

1. Kervic GN, Shepherd WF. The pattern of corneal graft rejection. Cornea 1990;9:234-7.
2. Wilson SE, Kaufman HE. Graft failure after penetrating keratoplasty. Surv Ophthalmol 1990;34:325-56.
3. Khodadoust AA, Silverstein AM. Transplantation and rejection of individual cell layers of the cornea. Invest Ophthalmol 1969;8:180-95.
4. Smolin G, Goodman D. Corneal graft reaction. Int Ophthalmol Clin 1988;28:30-6.
5. Boisjoly HM, Bernard PM, Dube I, Laughrea PA, Bazin R, Bernier J. Effect of factors unrelated to tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol 1989;107:647-54.
6. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection: oral versus single pulse therapy. Ophthalmology 1991;98:329-33.
7. Hill JC, Maske R, Watson PG. The use of a single pulse of intravenous methylprednisolone in the treatment of corneal graft rejection: a preliminary report. Eye 1991;5:420-4.
8. Hill JC. Corticosteroid in corneal graft rejection: double versus single pulse therapy. Cornea 1994;13:383-8.
9. Silverman ED, Myones BL, Miller JJ. Lymphocyte subpopulation alterations induced by intravenous megadose pulse methylprednisolone. J Rheumatol 1984;11:287-90.
10. Borel JF, Feurer C, Gubler HU. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468-75.
11. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A: background, immunology, and pharmacology. Cornea 1990;9:184-95.
12. Calne RY, Rolles K, White DJ, et al. Cyclosporin-A in clinical organ grafting. Transplant Proc 1981;13:349-58.
13. Starzl TE, Iwatsuki S, Klintmalm G, et al. Liver transplantation, 1980, with particular reference to cyclosporin-A. Transplant Proc 1981;13:281-5.
14. Sundmacher R, Reinhard T, Heering P. Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients: a retrospective study. Ger J Ophthalmol 1992;1:432-6.
15. Hill JC. Systemic cyclosporin in high-risk keratoplasties: short- versus long-term therapy. Ophthalmology 1994;101:128-33.
16. Hill JC. The use of cyclosporin in high-risk keratoplasties. Am J Ophthalmol 1989;107:506-10.
17. Homan WP, Fabre JW, Millard PR, Morris PJ. Effect of cyclosporin A upon second-set rejection of rat renal allografts. Transplantation 1980;30:354-7.
18. Gratwohl A, Forster I, Speck B. Skin grafts in rabbits with cyclosporin A: absence of induction of tolerance and untoward side effects. Transplantation 1981;31:136-8.
19. Hess AD, Esa AH, Colombani PM. Mechanisms of action of cyclosporin: effect of cells of the immune system on subcellular events in T cell activation. Transplant Proc 1988;20:29-40.
20. Margreiter R, Huber C, Spielberger M, Konig P. Cyclosporine in the treatment of acute cadaveric kidney graft rejection refractory to high-dose methylprednisolone. Transplantation 1983;36:203-4.
21. Margreiter R, Lang A, Koenig P, et al. Cyclosporine in the treatment of acute allograft rejection refractory to high-dose methylprednisolone: results of a prospectively randomised trial. Transplant Proc 1984;16:1202-4.
22. Rolfe MW, Kunkel SL, Demeester SR, et al. Expression of interleukin-6 in association with rat lung reimplantation and allograft rejection. Am Rev Respir Dis 1993;147:1010-6.
23. Ford HR, Hoffman RA, Tweardy DJ, et al. Evidence that production of interleukin-6 within rejecting allograft coincides with cytotoxic T lymphocyte development. Transplantation 1991;51:656-61.
24. Keenan RJ, Zeevi A, Iacono AT, et al. Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery 1995;118:385-91.
25. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporine in high-risk corneal transplants [see comments]. Ophthalmology 1989;96:1144-50.
26. Goichot-Bonnat EL, Pouliquen YJM. Topical cyclosporin A in high-risk keratoplasty. In: Cavanagh HD, editor. Third international congress on the cornea. New York: Raven Press, 1988:399-401.
27. Charnick SB, Nedelman JR, Chang CT, et al. Description of blood pressure changes in patients beginning cyclosporin A therapy. Ther Drug Monit 1997;19:17-24.
28. Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR. Topical FK-506 prevents experimental corneal allograft rejection. Cornea 1995;14:157-60.
29. Hikita N, Lopez JS, Chan CC, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997;38:901-9.